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Reversal of trimethoprim.induced antikaliuresis. High-dose tn-
methoprim-sulfamethoxazole (TMP-SMX) causes hyperkalemia, thought
to result from TMP-induced blockade of amiloride-sensitive Na-chan-
nels in the distal nephron. The present study was performed in anesthe-
tized dogs to determine if increasing distal sodium delivery affects this
antikaliuretic effect. In Group 1, intrarenal infusion of vehicle did not alter
renal function. In Group 2, i.v. infusion of amilonide led to diuresis,
natriuresis and antikaliuresis associated with a reduction of the transtu-
bular potassium gradient (TTKG) in both kidneys. Intrarenal infusion of
TMP (0.2 mg/kg/mm) into the left kidney did not further alter these
parameters. In groups 3 and 4, intrarenal infusion of TMP caused an
ipsilateral diuresis, natniuresis, antikaliuresis and a reduction in (11KG)
without affecting the contralateral kidney. The TMP infusion was followed
by furosemide (20 mg i.v.) in group 3 and acute saline loading in group 4.
Despite continuous TMP infusion, both furosemide and saline loading
reversed the antikaliuretic effect of TMP in the ipsilateral kidney and was
associated with a similar kaliuresis, diuresis, natriuresis and decrease in
urine osmolality in both kidneys. The 11KG following furosemide or
saline loading increased in the ipsilateral kidney and decreased in the
contralateral kidney. In all groups the systemic and renal hemodynamics
remained unchanged. These results suggest that acute administration of
TMP inhibits the amiloride-scnsitive Na-channel and KF secretion in the
distal nephron. Maneuvers that increase distal Na delivery can abrogate
TMP's antikaliuretic effect due, in part, to an increase of the low TTKG
observed with TMP.
Recently we reported that hyperkalemia frequently develops in
patients treated with high-dose trimethoprim-sulfamethoxazole
(TMP-SMX) (TMP 20 mg/kg/day and SMX 100 mg/kg/day) [1].
The hyperkalemia typically occurred 7 to 10 days after the
initiation of therapy, and the serum potassium (K) concentration
was noted to progressively increase after the initiation of high-
dose TMP-SMX therapy and decrease upon its discontinuation
without specific therapy. Other factors known to influence K
homeostasis could not be implicated and it was speculated that
the hyperkalemia induced by TMP-SMX therapy resulted from an
impaired ability of the kidney to excrete K F [I]. Other recent
vitro and in vivo studies have shown that TMP inhibits K
secretion in a dose-dependent fashion and reversibly blocks apical
sodium (Na) channels in the cultured A6 epithelial cell line [2, 3]
and impairs K secretion in the distal tubule by depolarizing the
lumen-negative transepithelial voltage in a micropuneture study in
the rat [4]. Based on these studies, it has been postulated that
TMP impairs Na transport in the distal tubule and reduces the
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lumen-negative potential difference generated by the Na trans-
port, thereby decreasing the electrical gradient favoring passive
K secretion. Therefore, TMP appears to inhibit K secretion in
a fashion similar to two structurally related cationic diuretics,
amiloride and triamterene.
The transtubular lumen-negative voltage gradient in the corti-
cal collecting tubule (CCT) is generated, in part, by active Na
reabsorption [51. A defect in Na reabsorption in the CCT would
prevent the formation of an optimal voltage gradient for hydrogen
ion and K secretion, thereby interfering with urinary acidifica-
tion and K excretion. This defect in Na transport has been
observed after the administration of amiloride in the turtle
urinary bladder [6] and in the isolated perfused CCT of the rabbit
[7]. In addition, when amiloride is administered to humans,
urinary pH cannot be lowered below 5.5 and K excretion is
impaired [81, features characteristic of a voltage-dependent de-
fect. Although TMP induces hyperkalemia by a voltage-depen-
dent mechanism, maneuvers which increase urine flow or the
delivery of Na and K to the CCT may attenuate the antikali-
uretic effect of TMP. The present study was performed to
determine if intravenous administration of furosemide or acute
saline loading, two maneuvers that increase urine flow and
delivery of Na and K to the distal nephron, could reverse
TMP-induced K retention, and gain insight into the mechanisms
of action by which this may occur. Indeed, if the antikaliuretic
effect of TMP can be reversed, this study would offer potential
therapeutic interventions to abrogate the development of hyper-
kalemia in patients requiring continued TMP or TMP-SMX
therapy.
Methods
Experiments were performed on female mongrel dogs weighing
25.1 0.5 kg. All dogs received a diet containing 60 mEq Na and
40 mEq K per day. On the morning of the acute experiment, the
dogs were anesthetized with sodium pentobarbital (30 mg/kg body
wt) intravenously. Light anesthesia was maintained throughout
the experiment by the administration of additional anesthetic, as
needed. An endotracheal tube was inserted and ventilation regu-
lated via a respirator. The urinary bladder was catheterized with a
Foley catheter for urine collection. A catheter was placed in the
thoracic aorta via a femoral artery to allow blood sampling, as well
as determination of mean arterial pressure (MAP). Another
catheter was subsequently placed in a femoral vein to allow
infusion of solutions. Through a left flank incision, the left renal
pedicle was carefully dissected and the renal artery isolated with
care to avoid disturbing the renal nerves. An electromagnetic flow
probe (model 400 series; Carolina Medical Electronics, King, NC,
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Table 1. Function of the right and left kidney in Group I
USA) was placed around the exposed renal artery and renal blood
flow (RBF) measured with an electromagnetic flowmeter (model
501, Carolina Medical Electronics). Zero flow was ascertained by
brief occlusion of the renal artery distal to the flow probe. A
25-gauge curved needle was gently inserted into the left renal
artery distal to the flow probe and maintained patent by infusion
of 0.9% saline at 0.4 ml/min. The left ureter was isolated and
cannulated with a polyethylene tube. After a priming dose of
inulin was administered intravenously, a constant infusion of
inulin dissolved in 0.9% saline was infused at a rate of 0.8 mI/mm
to maintain adequate blood levels. TMP was dissolved in 40%
propylene glycol, 10% ethyl alcohol, 1% benzyl alcohol and
adjusted to a pH of 8.0. This vehicle solution is similar to that
prepared for the intravenous form of Bactrim (TMPISMX) used
in humans [91.
Following a 60-minute equilibration period, three 10-minute
urine specimens were collected from the bladder and left ureter
with blood sampling at the midpoint of urine collection for
clearance determinations. Four groups of dogs were studied.
Group 1 (N = 5), vehicle solution. After control hemodynamic
and clearance measurements were obtained, the vehicle solution
alone was infused into the left renal artery at a rate of 0.4 mI/mm
for 90 minutes. Hemodynamic and 10-minute clearance measure-
ments were obtained during this infusion.
Group 2 (N = 5), intravenous infusion of amiloride followed by
intrarenal infusion of TMP into the left kidney. After the control
measurements were obtained, 5 mg of amiloride was administered
intravenously. Hemodynamic and clearance measurements were
obtained. Thirty minutes after the amiloride administration, TMP
was infused into the left renal artery at a rate of 0.2 mg/kg/mm.
Hemodynamic and clearance measurements were obtained for 40
minutes.
Group 3 (N = 5), intrarenal infusion of TMP into the left kidney
followed by intravenous administration of Jitrosemide. After the
control measurements were obtained, TMP was infused into the
left renal artery at a rate of 0.2 mglkglmin. Hemodynamic and
clearance measurements were obtained. Forty minutues later, 20
mg of furosemide was given intravenously. Hemodynamic and
clearance measurements were taken for 40 minutes while intra-
renal infusion of TMP was continued.
Group 4 (N — 5), intrarenal infusion of TMP Jbllowed by
intravenous saline loading. After the control measurements were
obtained, TMP was infused into the left renal artery at a rate of
0.2 mg/kg/mm. Hemodynamic and clearance measurements were
obtained. Forty minutes later, acute saline loading was achieved
with 0.9% saline infused intravenously at 2 ml/kg/min for 15
minutes, followed by a constant infusion of 0.5 mI/kg/mm for an
additional 15 minutes. Hcmodynamic and clearance measure-
ments were done throughout the period of saline loading, while
intrarenal infusion of TMP was continued.
In all groups, urinary losses were replaced with 0.9% saline
containing 10 mEq/liter of KC1.
Inulin was determined on an autoanalyzer (Technicon Instru-
ments, Tarrytown, NY, USA). Na and K concentrations were
determined by direct potentiometry on a NOVA I Na/K
analyzer (NOVA Biomedical, Newton, MA, USA). Osmolality
was determined on an osmometer (Fiske Osmometer; Fiske
Associates, Norwood, MA, USA). Arterial blood hematocrit was
measured by the centrifugation method at 10,000 rpm for five
minutes on an Adams Autocrit Centrifuge (Clay-Adams, NY,
USA). GFR was determined by inulin clearance. Clearances were
calculated by standard methods.
The transtubular K gradient ('VFKG), an indirect measure of
the net K secretion in the CCT, was derived by the formula [10,
111: TTKG = (U/P)K/(U/P)0S,,,, where (U/P)K is the urine-to-
plasma K concentration ratio and (U/P)0,,, the urine-to-plasma
osmolality ratio.
All results are expressed as means SE. Experimental results
were subjected to one-way analysis of variance for repeated
measures, and the statistical significance for multiple comparisons
was determined by the Bonferroni test. The statistical significance
of the difference between the paired or unpaired values was
determined by Student's f-test. Results were considered significant
if P <0.05.
Results
Table 1 summarizes the results of hemodynamic and clearance
measurements in Group 1. During the control period, the urine
flow rate, osmolality, Na and K excretion, and inulin clearance
were similar between the right and left kidney. Plasma osmolality
was 306 4 mOsm/kg H20, Na concentration 146 I mEq/
liter, and urine pH 7.63 0.20. After infusion of the vehicle
solution into the left kidney, there was no significant alteration in
MAP, RBF, and inulin clearance. The urine flow rate, Na and
KF excretion, and osmolality in both kidneys did not change
significantly. Serum K concentration, hematocrit, plasma osmo-
lality and urine pH remained stable.
Table 2 shows the results of hemodynamic and clearance
measurements in Group 2. During the control period, the urine
flow rate, osmolality, Na and K excretion, and inulin clearance
were similar between the right and left kidney. Plasma osmolality
was 306 2 mOsm/kg H20, Na concentration 147 1 mEq/
V mi/mm
R L
U,,
R
mOsni/kg
H,O
L R
UN,V Eq/
mm
L
UKV
R
p.Eq/
mm
L
C1,, mi/mm
R L
CTR 0.9 0.8 1,078 1,174 54 55 50 41 30.9 27.4 236 112 44.2 4.1
±0.3 ±0.4 ±202 ±176 ±25 ±11 ±3 ±8 ±4.9 ±2.7 ±20 ±5 ±0.7 ±0.1
Vehicle 1.1 0.7 956 1,044 52 51 45 36 27.2 26.6 240 112 45.2 4.1
solution ±0.3 ±0.2 ±197 ±202 ±25 ±15 ±5 ±6 ±4.6 ±2.8 ±17 ±5 ±0.6 ±0.1
P value NS NS NS NS NS NS NS NS NS NS NS NS NS NS
RBF MAP
ml/ mm
mm Hg
Hct mEq/
% liter
Values are means ± SE; N = 5. Abbreviations arc: V, urine flow rate; Uom, urine osmolality; UNaV, absolute urinary sodium excretion; UKV, absolute
urinary potassium excretion; Ci,, inulin clearance; RBF, renal blood flow; MAP, mean arterial pressure; Hct, hematocrit; K, plasma potassium
concentration; R, right kidney; L, left kidney; CTR, control; NS, not significant.
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Table 2. Effects of intravenous administration of amiluride, followed by intrarenal infusion of TMP into the left kidney (Group 2)
U0,11 mOsm!kg
V mI/mm
_____
UNaV p.Eq/min UKV p.Eq/min C1, mI/mm
R L R L R L R L R L
CTR 0.6 0.5 1,087 1,372 31 24 63 44 33,6 34.7 228 124 48.0 4.0
±0.2 ±0.1 ±184 ±178 ±5 ±8 ±13 ±12 ±4.6 ±2.7 ±12 ±3 ±1.5 ±0.1
AML 1.5 2.1 595 895 93 98 22 22 31.6 33.4 232 125 49.0 4.0
±0.4 ±0.7 ±141 ±214 ±27 ±37 ±3 ±6 ±3.7 ±5.4 ±12 ±3 ±1.5 ±0.1
TMP 1.6 2.3 537 634 90 104 21 21 30.1 27.5 230 125 48.3 4.0
±0.6 ±0.6 ±178 ±109 ±30 ±46 ±6 ±8 ±1.9 ±2.7 ±15 ±3 ±1.7 ±0.1
P (AML vs. CTR) <0.05 <0.05 <0.01 <0.05 <0.05 <0.05 <0.01 <0.01 NS NS NS NS NS NS
P (TMP vs. AML) NS NS NS NS NS NS NS NS NS NS NS NS NS NS
Values are means ± Sc, N = 5. Abbreviations are: V, urine flow rate, U0,,, urine osmolality; UNaV, absolute urinary sodium excretion; UKV, absolute
urinary potassium excretion; C111, inulin clearance; RBF, renal blood flow; MAP, mean arterial pressure; Hct, hematncrit; K' plasma potassium
concentration; R, right kidney; L, left kidney; CTR, control; AML, amiloride; TMP, trimethuprim; NS, not significant.
liter, and urine pH 7,58 ± 0.26. After intravenous administration
of amiloride, the urine flow rate and Na excretion increased, and
urine osmolality decreased significantly in both kidneys. Urinary
K excretion decreased significantly in both kidneys. There were
no significant changes in inulin clerance, RBF, or MAP. Hemat-
ocrit, plasma K and Na concentrations, and osmolality did not
change significantly. Urine pH was not significantly altered
(7.54 ± 0.19). After intrarenal infusion of TMP into the left
kidney, there was no significant alteration in MAP, RBF, or inulin
clearance, The urine flow rate, Na and K excretion, and
osmolality in both kidneys did not change significantly. Serum K
concentration, hematocrit, plasma osmolality and urine pH re-
mained stable.
Table 3 summarizes the results of hemodynamic and clearance
measurements in Group 3. During the control period, the urine
flow rate, osmolality, Na and K' excretion, and inulin clearance
were similar in the two kidneys. Plasma osmolality was 311 ± 2
mOsm/kg H20, Na concentration 148 ± 1 mEq/liter, and urine
pH 7.55 ± 0.25. After intrarenal infusion of TMP, the urine flow
rate and Na excretion increased in the left kidney but showed no
significant changes in the right kidney. Urine osmolality and K
excretion decreased significantly only in the left kidney and
remained unchanged in the right kidney. There were no signifi-
cant alterations in RBF, MAP, or inulin clearance in either
kidney. Urine pH was not significantly altered (7.39 ± 0.18). After
intravenous infusion of furosemide, the urine volume, Nat, and
K excretion increased and osmolality decreased markedly in
both kidneys and reached similar levels. There were no significant
changes in inulin clearance in either kidney, and MAP remained
stable; however, RBF increased significantly. Serum K concen-
tration, hematocrit, plasma osmolality and urine pH remained
stable both during TMP infusion and after furosemide adminis-
tration.
Table 4 summarizes the results of hemodynamic and clearance
measurements in Group 4. During the control period, the urine
flow rate, osmolality, Na' and K excretion, and inulin clearance
were similar in the two kidneys. Plasma osmolality was 308 ± 3
mOsm!kg H20, Na concentration 147 ± 1 mEq!litcr, and urine
pH 7.64 ± 0.31. After intrarenal infusion of TMP, the urine flow
rate and Na excretion increased only in the left kidney and
showed no significant changes in the right kidney. Urine osmola-
lity and K excretion decreased significantly only in the left kidney
and remained unchanged in the right kidney. There were no
significant alterations in inulin clearance in either kidney, RBF, or
MAP. Urine pH was not significantly changed (7.52 ± 0.20). After
intravenous saline loading, the urine volume, Na, and K
excretion increased and osmolality decreased markedly in both
kidneys and reached similar levels. There were no significant
changes in RBF, MAP or inulin clearance in either kidney. Serum
K concentration, plasma osmolality and urine pH remained
stable both during TMP infusion and after saline loading. Hemat-
ocrit remained stable during TMP infusion but decreased signif-
icantly after saline loading.
Figure 1 illustrates the changes in the TTKG in Groups 2, 3,
RBF MAP
ml! mm
mm Hg
Hct mEqI
% liter
Table 3. Effects of intrarenal infusion of TMP into the left kidney, followed by intravenous infusion of furosemide (Group 3)
V ml/mmn
U0111, mOsm/kg
''2° UNaV p.Eq!min UKV p.Eq/mmn C1,_mI/mm
R L R L R L R L R L
RBF MAP
ml! mm Hct mEq/
mm Hg % liter
CTR 0.7 0.7 1,122 1,155 33 37 40 41 27.2 27.4 232 105 35.0 3.8
±0.2 ±0.2 ±167 ±218 ±5 ±6 ±4 ±5 ±3.1 ±2.7 ±37 ±4 ±1.8 ±0.1
TMP 0.9
±0.2
1.8
±0.4
1,064
-'-193
788
±171
36
±4
78
±26
39
±3
16
±4
29.2
±3.9
26.6
±2.8
234
±36
103
±4
35.0
±1.8
3.9
±0.1
FM 7.5
±1.3
7.4
±0.9
341
±13
350
±7
1,088
±172
984
±131
105
±20
92
±13
28.6
±3.1
23.9
±2.0
256
±34
106
±3
34.3
±1.3
3.9
±0J
P (TMP vs. CTR) NS <0.05 NS <0.05 NS <0.05 NS <0.01 NS NS NS NS NS NS
P (FM vs. TMP) <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 NS NS <0.01 NS NS NS
Values are means ± sa,N = 5. Abbreviations are: V, urine flow rate; Uosm, urine osmolality; U1V, absolute urinary sodium excretion; UKV, absolute
urinary potassium excretion; C,,, inulin clearance; RBF, renal blood flow; MAP, mean arterial pressure; Hct, hcmatocrit; plasma potassium
concentration; R, right kidney; L, left kidney; CTR, control; TMP, trimethoprim; FM, furosemide; NS, not significant.
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Table 4. Effects of intrarenal infusion of TMP into the left kidney, followed by an acute intravenous saline load (Group 4)
V mI/mm
R L
U0 mOsm/kg
H20
R L
UNaV p.Eq/min
R L
UKV pEq/
mm
R L
C mI/mm
R L
RBF
ml!
mm
MAP
mm
Hg
Hct
%
P
mEq/
liter
CTR 0.6
0.2
0.4
0.1
1,156 1,054
281 175
71
30
63
32
31 28
7 6
30.7
4.0
26.8
1.5
236
10
109
6
37.4
2.2
4.1
0.1
TMP 0.8
0.1
1.2
0.3
1,056 766
277 102
66
22
111
20
25 11
5 3
29.7
3.7
29.0
1.7
238
8
110
6
36.6
2.2
4.2
0.1
SL 3.6
0.5
3.7
0.9
497 464
115 50
280
72
292
62
40 42
10 7
29.4
2.7
26.9
2.1
256
25
111
4
32.8
2.5
4.2
0.1
P (TMP vs. CTR) NS <0.05 NS <0.05 NS <0.05 NS <0.01 NS NS NS NS NS NS
P (SL vs. TMP) <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.05 <0.01 NS NS NS NS <0.01 NS
Values are means SE. N = 5. Abbreviations are: V, urine flow rate; U0sm, urine osmolality; UNUV, absolute urinary sodium excretion; UKV, absolute
urinary potassium excretion; C1,,, inulin clearance; RBF, renal blood flow; MAP, mean arterial pressure; Hct, hematocrit; K, plasma potassium
concentration; R, right kideny; L, left kidney; CTR, control; TMP, trimethoprim; SL, saline loading; NS, not significant.
and 4. During the control period, the 11KG was similar in the left
and right kidneys in all groups. In Group 2, the TFKG decreased
significantly and similarly in both kidneys after intravenous ad-
ministration of amiloride and was not further altered with intra-
renal infusion of TMP into the left kidney. In Group 3, the 11KG
decreased sharply only in the left kidney after intrarenal infusion
of TMP and remained unchanged in the right kidney. After
intravenous furosemide administration, the TTKG fell in the right
kidney but rose significantly in the left kidney despite continuous
intrarenal infusion of TMP, so that the TTKG was similar in both
kidneys. In Group 4, intrarenal infusion of TMP led to a marked
decrease in the 11KG in the left kidney but not in the right
kidney. After saline loading, the TFKG decreased in the right
kidney but increased significantly in the left kidney while TMP was
continuously infused into the left kidney. As a result, the TTKG
became similar in both kidneys.
Discussion
The present study demonstrates that intrarenal administration
of TMP results in an ipsilateral natriuresis, diuresis and a marked
reduction in K excretion, and that these effects occur without
significant changes in renal hemodynamics. Intravenous adminis-
tration of amiloride leads to a diuresis and natriuresis but reduces
K excretion. Intrarenal infusion of TMP fails to further alter the
effects of amiloride in the ipsilateral or contralateral kidney.
Intravenous administration of furosemide or saline loading in-
duces a large increase in urine flow rate, natriuresis, and kaliuresis
in both kidneys. Despite the continuous intrarenal infusion of
TMP, furosemide administration or saline loading reverses the
ipsilateral antikaliuresis induced by TMP.
The renal excretion of K is largely dependent on K secretion
into the luminal fluid and the tubular fluid flow rate beyond the
distal convoluted tubule. In the cortical collecting tubule, electro-
genic Na reabsorption provides the negative intraluminal volt-
age needed for K secretion [5]. The Na transport across the
epithelial cell in this nephron segment requires Na entry through
the amiloride-sensitive Na' channel in the apical plasma mem-
brane and Na exit mediated by the Na-K-ATPase pump
located in the basolateral membrane. Blockade of the Na'
channel by amiloride, pentamidine, and TMP has been demon-
strated in vitro in the A6 distal nephron cell and is thought to be
responsible for the antikaliuretic effect of these agents [2, 12]. In
support of this antikaliuretic mechanism, in vivo microperfusion
studies in the rat have shown that perfusion of the distal tubule
with TMP markedly inhibits distal tubule K secretion and
depolarizes the lumen-negative transepithelial voltage [4]. In the
present study, the marked decrease in K excretion occurred only
in the kidney receiving TMP infusion and was associated with an
ipsilateral natriuresis and diuresis. In addition, these renal tubular
actions of TMP were prevented by pretreatment with amiloride.
These findings are in keeping with the notion that blockade of the
amiloride-sensitive Na channel by TMP is the primary cause of
the antikaliuresis.
The 11KG reflects the process of K secretion in the CCT [13,
14]. To be valid, the calculation of the 11KG requires that urine
osmolality be equal to or greater than that of plasma, such as what
may occur under hydropenic conditions, and the formula adjusts
for water reabsorption in the medullary collecting duct. The
11KG assumes that relatively small amounts of solutes are
reabsorbed in the medullary collecting duct to avoid underesti-
mating the volume of water reabsorbed in this nephron segment
[13, 14]. Finally, the calculation of the TTKG assumes that there
is no substantial secretion or reabsorption of K in the medullary
collecting duct. In the present study, these assumptions are either
met or of little concern. These experiments were performed under
hydropenic conditions and the renal function of the experimental
kidney was compared with the contralateral kidney. Alterations in
tubular water or solute transport after intravenous administration
of amiloride, furosemide or acute saline loading are expected to
be similar in both kidneys.
The results of the administration of amiloride in Group 2
demonstrate the independence between the urine flow rate and
the process of K secretion in the distal nephron in renal K
excretion. Despite a significant increase in the urine flow rate after
intravenous infusion of amiloride, a marked reduction in K
excretion occurred in both kidneys. The large decrease in the
11KG caused by amiloride disclosed impaired K secretion in
both kidneys and was not further altered by intrarenal infusion of
TMP into the left kidney. There was also no further increase in
diuresis and natriuresis after TMP administration, indicating that
these two agents share similar properties in blocking Na chan-
nels and inhibiting K secretion, as noted above.
Intravenous administration of furosemide superimposed on
TMP infusion into the left kidney in Group 3 led to a marked
diuresis, natriuresis and kaliuresis in both kidneys, completely
abolishing the differences caused by TMP between the two
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A Fig. 1. The iranstubular K gradient in Group 2 (A), Group 3 (B), and
Group 4 (C). Abbreviations are: CTR, control; Lt, left kidney; Rt, right
kidney. In Group 2 (N = 5), amiloride (AML) was administered intrave-
nously and trimethoprim (TMP) infused into the left kidney. In Group 3
(N = 5), trimethoprim (TMP) was infused into the left kidney and
furosemide (FM) administered intravenously. In Group 4 (N = 5),
trimethoprim (TMP) was infused into the left kidney and saline loading
(SL) administered intravenously. Symbols are: (0) right; (•) left; fP <
0.01 compared with the CTR period; *P < 0.05 compared with the period
when TMP was infused into the left kidney.
t
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In Group 3, the ITKG after intrarenal infusion of TMP in the
left kidney decreased markedly, whereas the gradient was not
affected in the right kidney. The large difference in the TTKGs
was abolished after a high rate of urine flow was established in
both kidneys with intravenous furosemide infusion. Specifically,
the TTKG decreased in the right kidney and increased in the left
kidney. The effects of a high urine flow rate on the TTKG and
renal K excretion were examined previously in humans [15]. The
TFKG in subjects treated with a mineralocorticoid was much
higher when they were on a K-repleted diet than when they were
on a low K diet. A high urine flow rate induced by the
administration of furosemide abolished the differences in the
TTKG produced by the two diets. As a result, the urinary K
excretion during a low K diet became similar to that on a K'
repleted diet. Therefore, the conservation of K during the period
of low K diet was reversed by a furosemide-induced high urine
flow rate [15].
Another method used in the present study to increase urine
flow rate and Na delivery to the CCT was intravenous saline
loading in Group 4. Kaliuresis was diminished unilaterally in the
left kidney after intrarenal TMP infusion, associated with a
marked ipsilateral decrease in the TT'KG. An acute saline load
increased urine flow rate and Na excretion to similar levels in
both kidneys. The difference in TTKG in the two kidneys caused
by unilateral TMP infusion was abolished by saline loading, which
induced a similar degree of kaliuresis on both sides despite
continuous infusion of TMP in the left kidney. Previous studies
have shown that a high urinary flow rate can enhance K
excretion in spite of an unchanged TTKG [15]. These results,
however, were observed when the TTKG was approximately 6.0
[15]. It is evident from our study that raising the TTKG is critical
in reversing the antikaliuretic effect of TMP because increasing
the urinary flow rate alone below a critical level is insufficient to
accomplish this goal.
The mechanisms whereby the low TTKG during TMP infusion
is increased by furosemide or saline loading are not clear, but
several possibilities need to be considered. Both procedures
increase delivery of tubular flow rate as well as Na and K to the
CCT. In the CCT, both high-selective and low-selective, amilo-
ride-inhibitable Na channels, as well as amiloride-insensitive,
nonselective cation channels have been identified in the apical
membranes of the principal cell [16]. Studies in the CCT using the
patch-clamp technique have demonstrated that aldosterone in-
creases the activity of the apical membrane Na channel [17, 18].
Infusion of furosemide increases the number of open Na
channels in three hours, corresponding to an increase in the
plasma aldosterone concentration [17]. In the present study it is
conceivable that administration of furosemide augments both
amiloride-sensitive and amiloride-insensitive Na channel activity
8
6
4
2
0
*
*
t
C TMP SL
kidneys in the urine flow rate, and Na and K excretion. Hence,
the antikaliuresis induced by intrarenal TMP infusion was re-
versed by furosemide.
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in the CCT apical membrane. With an increase in Na delivery,
Na entry into the principal cell through the channels not
occupied by TMP may generate a lumen-negative electrical
driving force for K secretion and thus raise the TFKG. This
possibility is unlikely because the infusion of furosemide was too
short to observe an increased effect of aldosterone synthesis.
Furthermore, if enchancing Na channel activity accounts for the
furosemide-induced increase in TTKG in the TMP-treated kid-
ney, an increase in Na delivery by furosemide in the contralat-
eral kidney should also increase the TTKG. In fact, the opposite
occurred. On the other hand, if aldosteone synthesis is suppressed
after saline loading, the Na channel activity in the CCT may be
reduced [17]. An increase in Na delivery with saline loading in
this setting may lead to a decrease in the TTKG. However, TTKG
increased in the present study. In addition, the duration of the
saline loading was also too short to obtain an aldosterone effect.
Previous micropuncture studies have established that under
normal conditions the major bulk of the filtered K has been
reabsorbed as the tubular fluid emerges from the ioop of Henle
[19, 201, and the concentration of K is approximately 3 to 4 ms'i
in the early distal tubular fluid [19, 20]. The K concentration in
the CCT increases primarily due to K secretion. Insofar as the
volume of fluid emerging from the loop is not altered, the K
concentration in the CCT (and ultimately the TTKG) would
largely depend on the K secretion. Inhibition of fluid reabsorp-
tion in the proximal tubule and the loop of Henle by saline loading
or in the loop by furosemide has been shown to result in the
delivery of large amounts of K into the early distal tubule [19, 21,
22]. As a result, the K concentration in the fluid delivered to the
distal tubule is substantially increased [19]. This increase in the
concentration delivered in a large volume of fluid to the CCT
would minimize the contribution of K secretion in the CCT
(whether inhibited or stimulated) to the luminal fluid K concen-
tration and significantly modify the TTKG expected from K
secretion in the CCT. This may explain why the administration of
furosemide or saline loading limits the difference in TTKG
between the two kidneys despite continous inhbition of K
secretion in the CCT by TMP in the ipsilateral kidney (Fig. 1).
The TMP-induced blockade of Na channels and antikaliuresis
are dose-dependent, pH-sensitive and reversible [2—4, 23]. An
increase in the luminal fluid pH in the CCT may convert TMP
from a cationic, active form to an electroneutral, inactive form
[23]. The antikaliuresis of TMP is markedly attenuated by alka-
linization of urine with acetazolamide. The concentration of TMP
required to inhibit the amiloride sensitive Na current by 50% in
the A6 distal nephron cell was 340 .LM at pH 8.2 and 50 M at pH
6.3 [23]. The concentration of TMP in the rat distal tubule needed
to inhibit the transepithelial voltage by one half of the maximum
was estimated to be 100 LM at a urine pH of 6.5 [4]. In Group 3,
the concentration of TMP in renal plasma was calculated to be
116 rM and in the ultrafiltrate 65 .LM, assuming that 44% of TMP
is protein-bound [9]. Without significant tubular reabsorption, this
TMP concentration should be effective even in an alkaline tubular
fluid as it may be increased to 255 to 349 /.tM in the distal tubule
with a tubular fluid-to-plasma inulin ratio of 3.9—5.4, as reported
in the hydropenic dog [21, 24, 25]. It is conceivable that the
increase in the urine flow rate with furosemide or saline loading in
an alkaline urine dilutes the concentration of the active form of
TMP in the CCT, thereby diminishing the efficacy of TMP in
blocking the Na channel. This event, however, cannot totally
explain our findings because the administration of furosemide or
saline loading was preceded by TMP, which was also continuously
infused during the entire experimental period. Prievious mi-
cropuncture studies in the dog showed that the TF/P inulin ratio
decreased to 2.03 and 3.60 after diuresis was established with
furosemide and saline loading, respectively [21]. The TMP con-
centration in the distal tubular fluid after furosemide administra-
tion and saline loading would then be 131 and 233 tM, respec-
tively, concentrations sufficient to effectively block the Na
channel [23]. In addition, the urine pH was not significantly
changed after administration of furosemide or saline loading.
Our study offers therapeutic implications for patients at risk for
developing hyperkalemia while receiving TMP or TMP-SMX
therapy. Patients receiving this therapy are frequently immuno-
compromised, many from the acquired immune deficiency syn-
drome, and are typically characterized by inanition and volume
contraction. In this setting the administration of high-dose TMP
therapy, which may be life saving, may further exacerbate a
pre-existing negative Na balance. In these patients, an increase
in the apical Na channel activity in the CCT produced by volume
contraction [17] may be required to facilitate the K secretion and
maintain K balance. Administration of TMP blocks the amilo-
ride-sensitive Na channel in the CCT and may result in life-
threatening hyperkalemia under these circumstances [1, 2, 4]. This
side-effect of TMP may be mitigated by careful attention to the
volume status to ensure adequate expansion of the extracellular
fluid volume. As suggested by our findings, intravenous adminis-
tration of a loop diuretic could theoretically reverse the antikali-
uresis of TMP, but the practicality of its clinical use could be
hampered by its propensity to cause volume contraction. In
patients who develop hyperkalemia and volume contraction with
TMP-SMX therapy, acute saline loading may correct hyperkale-
mia and allow continuous therapy with this antibiotic. Our
findings that administration of furosemide or saline loading raises
the low TTKG induced by TMP could serve as a simple early
bedside test to determine whether TMP is altering KF transport in
the CCT even before hyperkalemia ensues and/or whether appro-
priate volume expansion has reversed the antikaliuresis of TMP.
These possibilities need to be tested clinically.
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